Why did Moderna release incomplete trial data?

Question

Accepted Answer

Moderna Released Incomplete Trial Data Due to Concerns Over Leaks and SEC Compliance

Moderna released partial findings from its vaccine trial on May 18, 2020, primarily out of concerns that the information might be leaked and to comply with Securities and Exchange Commission (SEC) regulations regarding material information. The company's leadership, including CEO Stéphane Bancel, believed that the incomplete results constituted material information that should be disseminated to all investors simultaneously, especially given that external entities like the National Institutes of Health (NIH) might have had access to the data.
Concerns Over Data Leakage Prompted Early Disclosure

Moderna's leadership expressed worries that sensitive trial information had been seen by too many individuals, including those at the NIH. CEO Stéphane Bancel communicated to investors that the company decided to make the partial findings public because of a concern that the data would be leaked. This perceived risk of an uncontrolled release of information necessitated a controlled, official announcement to ensure all stakeholders received the news concurrently.
Compliance with SEC Rules Cited as a Reason for Release

A Moderna spokeswoman indicated to Reuters that the company felt compelled to release the information to adhere to Securities and Exchange Commission (SEC) rules. Publicly traded companies are subject to regulations that mandate the timely disclosure of any information that could materially affect the company's stock price. By releasing the partial trial data, Moderna aimed to fulfill its obligation to inform the market about significant developments, even if those developments were not yet fully validated.
Incomplete Data Release Led to Stock Surge and Scientific Scrutiny

The announcement of preliminary antibody data on May 18, 2020, resulted in a 20% surge in Moderna's stock price, reaching a peak of $80. However, this early release of incomplete findings also drew criticism from some scientists. Figures like Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, described the move as "science by press release," suggesting that such disclosures should ideally wait until all test subjects' results are available for a comprehensive analysis.
Early Data Release Incentivized by Potential Stock Value and Executive Compensation

The scenario highlights the high-stakes environment for biotech firms like Moderna, where development milestones can significantly impact stock valuation and executive compensation. The company's chief medical officer, Tal Zaks, and CEO Stéphane Bancel had engaged in substantial share sales, netting millions of dollars. While these sales were often conducted under pre-arranged plans (10b5-1 plans) designed to avoid insider trading accusations, the timing of some transactions, particularly Zaks' increased sales just before positive news, underscores the financial incentives for executives to maintain a positive stock performance, which can be influenced by the release of development progress, even if partial.

Reading history

Hide →

This history is cleared when the page is closed.

Why did Moderna release incomplete trial data?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends